Tricuspid valve regurgitation is more common than one might think. It often stems from left valve disease and associated with increased mortality and hospitalization due to heart failure, which is not easy to treat. Currently, guidelines list surgery as the recommended treatment, though this option is quite complex and might entail complications and mortality risk.…
TAVI-in-TAVI with Balloon-Expandable Valves
TAVI (Transcatheter Aortic Valve Implantation) has proven to be beneficial and is currently performed in increasingly younger and lower-risk patients. However, as with surgical bioprostheses, structural deterioration, whether due to stenosis or regurgitation, is one of the challenges we must address. While currently uncommon, this is an issue we will probably see more and more…
Post-TAVI Prosthesis-Patient Mismatch
Prosthesis-patient mismatch (PPM) occurs when the effective orifice area (EOA) after valve placement is significantly smaller compared with the patient’s body surface area (BSA), resulting in an increased transprosthetic residual gradient. The presence of PPM, especially in various surgical series, has been associated with long-term adverse clinical events. In relation to transcatheter aortic valve implantation…
Predictors and Evolution of Need for PPM after TAVR with Self-Expanding Valves
In the context of TAVR, one of the current challenges is the need for permanent pacemaker implantation (PPM), especially when using self-expanding valves (SEV). The information available in this regard remains controversial; while some studies suggest new PPM implantation will have no significant effect on clinical evolution, others have associated them with worse prognosis. As…
Degenerative Mitral Regurgitation: Impact on Post-Procedural Gradient
Primary or degenerative mitral regurgitation (MR) occurs frequently. Even though surgery continues to be the standard treatment at present, it remains risky for one group of patients, which makes edge-to-edge mitral valve repair (MV-TEER) a viable alternative. We are well aware that moderate to severe MR is associated with worse prognosis. However, post procedural mean…
MyVal Device in Non-Calcified Severe Aortic Regurgitation
Due to the proven long-term results and substantial increase in the number of transcatheter aortic valve implantation (TAVI) procedures conducted, the application of TAVI has been extended to clinical situations outside the original scope, such as non-calcified aortic regurgitation (NCAR). Device placement in these new scenarios entails a technical challenge due to the absence of…
Predictors and Evolution of Permanent Pacemaker After TAVR with Self-Expanding Valves
Transcatheter aortic valve replacement (TAVR) has shown remarkable benefits and continues to advance towards lower-risk patients and younger ages. However, one of its limitations lies in the demand for a permanent pacemaker (PPM), which during TAVR early stages with self-expanding valves reached 30%. Uncertainty persists regarding the evolution of patients undergoing PPM implantation after TAVR,…
SOLACI-SBHCI 2023 | TAVI – Minimizing Risks, Optimizing Outcomes & Impact of the Index Procedure on Future Options – Dr. Ole De Backer
Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Ole De Backer, entitled “TAVI – Minimizing Risks, Optimizing Outcomes & Impact of the Index Procedure on Future Options”
SOLACI-SBHCI 2023 | TAVR – Lifetime Management of Patients with Aortic Stenosis – Dr. Ole de Backer
Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Ole de Backer, entitled “TAVR – Lifetime Management of Patients with Aortic Stenosis”
Moderate Aortic Stenosis: We Should Start Assessing It More Thoroughly
Moderate aortic stenosis (MAS) encompasses a broader spectrum than severe aortic stenosis. However, its progression has not yet been fully elucidated. While there are reports suggesting that this condition is not as benign as initially believed, there is a need to consider early interventions in certain instances. Researchers conducted an analysis from January 2016 to…
SOLACI-SBHCI 2023 | Mitral Valve Interventions beyond the TEER Era: Time to Re-Evaluate Innovation Priorities?- Dr. Eberhard Grube
Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Eberhard Grube, entitled “Mitral Valve Interventions beyond the TEER Era: Time to Re-Evaluate Innovation Priorities?”